Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

By Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Current Medical Research and Opinion, Vol. 21, Iss. 12, 2005-12 ,pp. : 1895-1903

Informa Healthcare

Access to resources Recommend Favorite

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study

By Recker R.   Weinstein R.   Chesnut C.   Schimmer R.   Mahoney P.   Hughes C.   Bonvoisin B.   Meunier P.  

Osteoporosis International, Vol. 15, Iss. 3, 2004-03 ,pp. : 231-237

Springer Publishing Company

Access to resources Recommend Favorite

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

By Kane John M.  

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 917-925

Informa Healthcare

Access to resources Recommend Favorite